Annual CFF
$25.98 M
+$26.93 M+2832.28%
December 31, 2023
Summary
- As of February 7, 2025, CDTX annual cash flow from financing activities is $25.98 million, with the most recent change of +$26.93 million (+2832.28%) on December 31, 2023.
- During the last 3 years, CDTX annual CFF has fallen by -$11.29 million (-30.30%).
- CDTX annual CFF is now -76.76% below its all-time high of $111.81 million, reached on December 31, 2015.
Performance
CDTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$182.00 K
-$239.31 M-100.08%
September 30, 2024
Summary
- As of February 7, 2025, CDTX quarterly cash flow from financing activities is -$182.00 thousand, with the most recent change of -$239.31 million (-100.08%) on September 30, 2024.
- Over the past year, CDTX quarterly CFF has dropped by -$190.00 thousand (-2375.00%).
- CDTX quarterly CFF is now -100.08% below its all-time high of $239.13 million, reached on June 30, 2024.
Performance
CDTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$238.86 M
-$182.00 K-0.08%
September 30, 2024
Summary
- As of February 7, 2025, CDTX TTM cash flow from financing activities is $238.86 million, with the most recent change of -$182.00 thousand (-0.08%) on September 30, 2024.
- Over the past year, CDTX TTM CFF has increased by +$212.88 million (+819.27%).
- CDTX TTM CFF is now -0.08% below its all-time high of $239.05 million, reached on June 30, 2024.
Performance
CDTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
CDTX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +2832.3% | -2375.0% | +819.3% |
| 3 y3 years | -30.3% | -100.7% | +822.4% |
| 5 y5 years | -53.7% | -100.7% | +822.4% |
CDTX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -41.7% | +2832.3% | -100.1% | +83.6% | -0.1% | >+9999.0% |
| 5 y | 5-year | -41.7% | +2832.3% | -100.1% | +83.6% | -0.1% | >+9999.0% |
| alltime | all time | -76.8% | +2832.3% | -100.1% | +91.2% | -0.1% | >+9999.0% |
Cidara Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$182.00 K(-100.1%) | $238.86 M(-0.1%) |
| Jun 2024 | - | $239.13 M(<-9900.0%) | $239.05 M(<-9900.0%) |
| Mar 2024 | - | -$93.00 K(-1262.5%) | -$346.00 K(-101.3%) |
| Dec 2023 | $25.98 M(-2832.3%) | $8000.00(>+9900.0%) | $25.98 M(-2.5%) |
| Sep 2023 | - | $0.00(-100.0%) | $26.64 M(-0.4%) |
| Jun 2023 | - | -$261.00 K(-101.0%) | $26.75 M(+3.3%) |
| Mar 2023 | - | $26.24 M(+3851.4%) | $25.90 M(-2823.1%) |
| Dec 2022 | -$951.00 K(-102.1%) | $664.00 K(+520.6%) | -$951.00 K(-102.7%) |
| Sep 2022 | - | $107.00 K(-109.6%) | $35.26 M(+2.7%) |
| Jun 2022 | - | -$1.11 M(+81.8%) | $34.34 M(-5.5%) |
| Mar 2022 | - | -$611.00 K(-101.7%) | $36.34 M(-18.5%) |
| Dec 2021 | $44.60 M(+19.6%) | $36.88 M(-4652.5%) | $44.60 M(+448.5%) |
| Sep 2021 | - | -$810.00 K(-191.3%) | $8.13 M(-35.8%) |
| Jun 2021 | - | $887.00 K(-88.4%) | $12.66 M(-19.4%) |
| Mar 2021 | - | $7.64 M(+1769.2%) | $15.71 M(-57.8%) |
| Dec 2020 | $37.28 M(+161.2%) | $409.00 K(-89.0%) | $37.28 M(-3.2%) |
| Sep 2020 | - | $3.72 M(-5.6%) | $38.51 M(-18.8%) |
| Jun 2020 | - | $3.94 M(-86.5%) | $47.42 M(+9.1%) |
| Mar 2020 | - | $29.21 M(+1680.0%) | $43.48 M(+204.7%) |
| Dec 2019 | $14.27 M | $1.64 M(-87.0%) | $14.27 M(+13.1%) |
| Sep 2019 | - | $12.63 M(>+9900.0%) | $12.62 M(-703.8%) |
| Jun 2019 | - | $0.00(0.0%) | -$2.09 M(-104.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | $0.00(-100.0%) | $49.69 M(-11.5%) |
| Dec 2018 | $56.15 M(+168.9%) | -$12.00 K(-99.4%) | $56.15 M(-27.1%) |
| Sep 2018 | - | -$2.08 M(-104.0%) | $76.98 M(-2.6%) |
| Jun 2018 | - | $51.77 M(+700.5%) | $79.06 M(+189.7%) |
| Mar 2018 | - | $6.47 M(-68.9%) | $27.29 M(+30.7%) |
| Dec 2017 | $20.88 M(-43.7%) | $20.81 M(>+9900.0%) | $20.88 M(-43.8%) |
| Sep 2017 | - | $3000.00(-40.0%) | $37.16 M(+0.2%) |
| Jun 2017 | - | $5000.00(-92.3%) | $37.10 M(-0.1%) |
| Mar 2017 | - | $65.00 K(-99.8%) | $37.12 M(+0.1%) |
| Dec 2016 | $37.09 M(-66.8%) | $37.09 M(<-9900.0%) | $37.09 M(>+9900.0%) |
| Sep 2016 | - | -$57.00 K(-328.0%) | $280.00 K(-6.4%) |
| Jun 2016 | - | $25.00 K(-39.0%) | $299.00 K(-99.6%) |
| Mar 2016 | - | $41.00 K(-84.9%) | $70.44 M(-37.0%) |
| Dec 2015 | $111.81 M(+257.1%) | $271.00 K(-813.2%) | $111.81 M(-0.2%) |
| Sep 2015 | - | -$38.00 K(-100.1%) | $112.09 M(+0.0%) |
| Jun 2015 | - | $70.17 M(+69.4%) | $112.08 M(+56.1%) |
| Mar 2015 | - | $41.41 M(+7484.4%) | $71.78 M(+129.3%) |
| Dec 2014 | $31.31 M(+2441.6%) | $546.00 K(-1237.5%) | $31.31 M(+1.8%) |
| Sep 2014 | - | -$48.00 K(-100.2%) | $30.77 M(-0.2%) |
| Jun 2014 | - | $29.87 M(+3078.1%) | $30.81 M(+3178.1%) |
| Mar 2014 | - | $940.00 K | $940.00 K |
| Dec 2013 | $1.23 M | - | - |
FAQ
- What is Cidara Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Cidara Therapeutics?
- What is Cidara Therapeutics annual CFF year-on-year change?
- What is Cidara Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Cidara Therapeutics?
- What is Cidara Therapeutics quarterly CFF year-on-year change?
- What is Cidara Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Cidara Therapeutics?
- What is Cidara Therapeutics TTM CFF year-on-year change?
What is Cidara Therapeutics annual cash flow from financing activities?
The current annual CFF of CDTX is $25.98 M
What is the all time high annual CFF for Cidara Therapeutics?
Cidara Therapeutics all-time high annual cash flow from financing activities is $111.81 M
What is Cidara Therapeutics annual CFF year-on-year change?
Over the past year, CDTX annual cash flow from financing activities has changed by +$26.93 M (+2832.28%)
What is Cidara Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of CDTX is -$182.00 K
What is the all time high quarterly CFF for Cidara Therapeutics?
Cidara Therapeutics all-time high quarterly cash flow from financing activities is $239.13 M
What is Cidara Therapeutics quarterly CFF year-on-year change?
Over the past year, CDTX quarterly cash flow from financing activities has changed by -$190.00 K (-2375.00%)
What is Cidara Therapeutics TTM cash flow from financing activities?
The current TTM CFF of CDTX is $238.86 M
What is the all time high TTM CFF for Cidara Therapeutics?
Cidara Therapeutics all-time high TTM cash flow from financing activities is $239.05 M
What is Cidara Therapeutics TTM CFF year-on-year change?
Over the past year, CDTX TTM cash flow from financing activities has changed by +$212.88 M (+819.27%)